<DOC>
	<DOCNO>NCT01284582</DOCNO>
	<brief_summary>Phase 1 Study : Safety , Immunogenicity Dose response ATH03 , new vaccine cholesterol ester transfer protein ( CETP ) , healthy male subject high density lipoprotein cholesterol ( HDLc ) blood concentration equal 80 mg/dl .</brief_summary>
	<brief_title>Safety , Immunogenicity Dose Response ATH03 , New Vaccine Against Cholesterol Ester Transfer Protein ( CETP )</brief_title>
	<detailed_description>This open-label Phase 1 study conduct three group 12 subject HDLc blood concentration equal 80 mg/dl single study center . 36 subject enrol .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male High density lipoprotein cholesterol ( HDLc ) blood concentration equal 80 mg/dl Clinically relevant pathological finding</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>CETP</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Inhibition</keyword>
</DOC>